IOVA
NasdaqIOVANCE BIOTHERAPEUTICS, INC.
Basic Materials · Biological Products, (No Diagnostic Substances)
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
🔒 price chart needs market-data feed$0
2017
$0
2018
$1.2M
2023
$164.1M
2024
$263.5M
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$263.5M
Net Income$-391.0M
Gross Profit—
Oper Income$-403.4M
EPS (dil)$-1.09
Rev/sh$0.59
FCF/sh$-0.75
Book/sh$1.56
Gross M—
Oper M-153.1%
Profit M-148.4%
FCF M-127.6%
ROE-56.0%
ROA-42.8%
ROIC-75.8%
R&D/Rev114.0%
Rev Y/Y60.6%
Rev 3Y CAGR—
EPS Y/Y14.8%
EPS 3Y CAGR—
FCF 3Y CAGR—
Payout—
Div/sh—
Shs Chg Y/Y+23.3%
Current Ratio3.20
Quick Ratio2.83
Debt/Eq—
Int Coverage—
Net Debt—
Total Debt—
Cash & Eq$169.1M
Total Assets$913.2M
Oper CF$-302.4M
Capex$33.8M
Free CF$-336.2M
Buybacks—
Equity$698.6M
Liabilities$214.6M
Shs Outstand0.45B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2017 | FY2018 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $1.2M | $164.1M | $263.5M |
| Gross Profit | — | — | — | — | — |
| Operating Income | $-92.9M | $-128.3M | $-460.6M | $-395.3M | $-403.4M |
| Net Income | $-92.1M | $-123.6M | $-444.0M | $-372.2M | $-391.0M |
| Diluted EPS | $-1.41 | $-1.27 | $-1.89 | $-1.28 | $-1.09 |
| Operating Cash Flow | $-78.7M | $-101.2M | $-361.8M | $-353.0M | $-302.4M |
| Free Cash Flow | $-79.7M | $-102.4M | $-384.1M | $-364.0M | $-336.2M |
COMMUNITY · $IOVA0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.